On Friday, Shares of Fiat Chrysler Automobiles NV (NYSE:FCAU), lost -1.95% to $13.60.
Just two months after producing the one millionth TorqueFlite eight-speed automatic transmission, FCA US facilities in Indiana celebrated another milestone – production of the one-millionth 948TE nine-speed automatic – and officially welcomed it into the TorqueFlite transmission family.
FCA North America Vice President of Manufacturing Brian Harlow, joined by the Company’s Vice President of Transmission Powertrain Jeffrey Lux, acknowledged the achievement during employee events recently at both the Indiana Transmission Plant I (ITPI) and the Tipton Transmission Plant, where the nine-speed has been built since May 2013.
“Five years ago, when Chrysler Group declared that it would build the nine-speed automatic transmission in Indiana, it was a huge vote of confidence in the skills, knowledge and expertise of our local workforce, especially because ITPI would be the first plant ever to build the nine-speed,” said Harlow. “This was a noteworthy challenge, but an even greater opportunity. There was a lot riding on our employees’ ability to deliver.
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
Shares of Computer Sciences Corporation (NYSE:CSC), declined -1.66% to $60.59, during its last trading session.
Computer Sciences Corporation declared that it has reached a definitive agreement to combine its government services unit, Computer Sciences Government Services (CSGov), with SRA upon the spin-off of that unit, plans for which were declared in May.
SRA is owned by a shareholder group led by Providence Equity Partners and SRA’s founder, Dr. Ernst Volgenau, in addition to members of its administration team. The transaction with SRA is targeted to close before the end of November 2015, upon the separation of CSC’s government services unit. That separation is intended to qualify as a tax-free transaction to CSC shareholders.
The combined company, to be named before closing, will become the largest pure-play IT services provider serving the U.S. government sector, with combined FY15 revenues of about $5.5 billion, nearly 19,000 employees and among the industry’s leading profit margins.
Computer Sciences Corporation provides information technology (IT) and professional services and solutions primarily in North America, Europe, Asia, and Australia. The company operates through Global Business Services, Global Infrastructure Services, and North American Public Sector segments.
Finally, Regeneron Pharmaceuticals Inc (NASDAQ:REGN), ended its last trade with -1.68% loss, and closed at $499.99.
Regeneron Pharmaceuticals and Sanofi declared that, in a new-pooled analysis of heterozygous familial hypercholesterolemia (HeFH) patients comprised in the ODYSSEY clinical trial program, Praluent (alirocumab) significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C).1 This analysis comprised 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C contrast to placebo (p less than 0.0001) in both arms.1 Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.1
Results of this analysis were presented recently at the ESC Congress 2015 in London, and the 78 week results from two of the four trials comprised in the analysis, ODYSSEY FH I and II, were conpresently published online in the European Heart Journal.
“About 20 percent of HeFH patients achieve LDL-C less than 100 mg/dL with statins. In this analysis, up to 75 percent of patients who added Praluent to standard-of-care achieved their LDL-C aims by week 24,” said John J. P. Kastelein, M.D., Ph.D., FESC, Professor of Medicine, Department of Vascular Medicine, Academic Medical Center/University of Amsterdam, the Netherlands. “Both Praluent 75 mg and 150 mg significantly reduced LDL-C levels below 100 mg/dL and sustained these lower levels through 78 weeks, offering patients and their doctors a flexible approach to treatment, with adverse events comparable to placebo.”
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
